IL6R and bronchitis: Our findings show that IL6R blockade significantly reduces the risk of COPD (OR = 0.71, 95% CI = 0.60–9.84) and asthma (OR = 0.82, 95% CI = 0.74–0.90), with protective trends for bronchitis, pulmonary embolism, and lung cancer.